Use of degarelix among patients with prostate cancer in daily practice

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/28608
• EU PAS number:
  EUPAS23879
• Study ID:
  28608
• Official title and acronym:
  Use of degarelix among patients with prostate cancer in daily practice
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  A population-based cohort study will be carried out using the UK’s general practitioner database, Optimum Patient Care Research Database (OPCRD), which includes prostate cancer patients initiating treatment of degarelix, leuprorelin, goserelin or triptorelin from 2010 till present. In this study, we will describe the characteristics, cardio events and urinary tract infections among patients with prostate cancer using degarelix, leuprorelin, goserelin or triptorelin in UK’s primary care.
• Study status:
  Finalised

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 01/02/2018

Actual: 01/02/2018

Study start date

Planned: 20/03/2018

Actual: 20/03/2018

Data analysis start date

Planned: 30/04/2018

Actual: 08/05/2018

Date of final study report

Planned: 31/05/2018

Actual: 22/05/2018

Sources of funding

Other

More details on funding

Harvey Walsh

Study protocol

Initial protocol

OPCG-1802_Protocol for Degarelix_V1.1

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable